Skip to content
BOLUS

Signal from the log

Novadip Biosciences

10,4 M€ · Belgium · Biotech

Novadip Biosciences fabrique un tissu vivant à partir des cellules souches du tissu graisseux du patient, disposées dans une matrice en trois dimensions, pour réparer de grandes pertes osseuses. Sa cible principale est la pseudarthrose congénitale du tibia, une maladie osseuse rare de l'enfant. Le tour est un financement convertible, et il débloque une tranche de dette de la Banque européenne d'investissement.

Article

Announced on , logged by the watch of 21 September 2026.

Operation
Funding round
Announced amount
10,4 M€
Country
Belgium
Sector
Biotech

What the log says

Editorial note, in French

Sujet traité. L'article donne les sources et la position de Bolus.

The investors

Led by New Science Ventures , with Fund+ , Wallonie Entreprendre , VIVES Fund , ORSA Tech , Sambrinvest , Noshaq , Invest.BW

Caveats
  • The stage of the round is not disclosed. A letter is never inferred from an amount or a track record.

Read the article on this operation (in French)

Provenance
Source eu-startups,sifted
Logged on 21 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).